Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) (RUXCOVID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04362137
Recruitment Status : Recruiting
First Posted : April 24, 2020
Last Update Posted : September 15, 2020
Sponsor:
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This is a randomized, double-blind, placebo-controlled, 29-day, multicenter study to assess the efficacy and safety of ruxolitinib + standard-of-care (SoC) therapy, compared with placebo + SoC therapy, in patients aged ≥12 years with COVID-19 pneumonia.

Condition or disease Intervention/treatment Phase
Cytokine Storm (Covid-19) Drug: Ruxolitinib Drug: Placebo Phase 3

Detailed Description:

This is a Phase III, multicenter, double-blind, randomized, placebo-controlled study to assess the efficacy and safety of ruxolitinib in patients aged ≥12 years with COVID-19 associated cytokine storm. The study will enroll patients to ruxolitinib or placebo, in addition to standard of care (SoC) per local practice. Patients who meet the inclusion/exclusion criteria will be randomized in a 2:1 ratio to either oral ruxolitinib 5 mg twice daily + SoC or oral matching-image placebo + SoC for a total of 14 days. An additional 14 days of study drug may be given, if in the opinion of the investigator, the patient's clinical signs and symptoms are not improved or worsen and the potential benefit outweighs the potential risk.

The study will include:

  • Screening period of 0-2 days.
  • Study period of 29 days (treatment of 14 days; an additional 14 days of study drug may be given, if in the opinion of the investigator, the patient's clinical signs and symptoms are not improved or worsen and the potential benefit outweighs the potential risk).

The primary objective is to evaluate the efficacy (as measured by a composite endpoint of proportion of patients who die, develop respiratory failure [require mechanical ventilation], or require intensive care unit care) of ruxolitinib + standard-of-care (SoC) therapy compared with placebo + SoC therapy, for the treatment of COVID-19 by Day 29.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 402 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)
Actual Study Start Date : May 2, 2020
Estimated Primary Completion Date : November 13, 2020
Estimated Study Completion Date : November 13, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Ruxolitinib 5 mg
Ruxolitinib 5 mg tablets twice daily (b.i.d.) for 14 days with possible extension of treatment to 28 days
Drug: Ruxolitinib
Ruxolitinib 5 mg tablets
Other Name: INC424

Placebo Comparator: Placebo
Matching-image placebo for 14 days with possible extension of treatment to 28 days
Drug: Placebo
Matching-image placebo




Primary Outcome Measures :
  1. Proportion of patients who die, develop respiratory failure [require mechanical ventilation] or require intensive care unit (ICU) care [ Time Frame: 29 days ]
    Efficacy is measured by a composite endpoint of proportion of patients who die, develop respiratory failure [require mechanical ventilation], or require intensive care unit [ICU] care for the treatment of COVID-19.


Secondary Outcome Measures :
  1. Clinical status [ Time Frame: Day 15, Day 29 ]
    Clinical status is measured with the 9-point ordinal scale. The scoring is - Uninfected patients have a score 0 (no clinical or virological evidence of infection). - Ambulatory patients (not in hospital or in hospital and ready for discharge) can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy defined as SpO2 ≥ 94% on room air) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation)). - Patients who die have a score 8.

  2. Percentage of patients with at least two-point improvement from baseline in clinical status [ Time Frame: Baseline, Day 15, Day 29 ]
    Percentage of patients with at least two points improvement in clinical status on the 9-point ordinal scale.

  3. Percentage of patients with at least one-point improvement from baseline in clinical status [ Time Frame: Baseline, Day 15, Day 29 ]
    Percentage of patients with at least one point improvement in clinical status on the 9-point ordinal scale.

  4. Percentage of patients with at least one-point deterioration from baseline in clinical status [ Time Frame: Baseline, Day 15, Day 29 ]
    Percentage of patients with at least one point deterioration in clinical status on the 9-point ordinal scale.

  5. Time to improvement in clinical status [ Time Frame: 29 days ]
    Time to improvement from baseline category to one less severe category of the 9-point ordinal scale.

  6. Mean change from baseline in the clinical status [ Time Frame: Baseline, Day 15, Day 29 ]
    Mean change from baseline in the 9-point ordinal scale.

  7. Mortality rate [ Time Frame: Day 15, Day 29 ]
    Mortality rate at Day 15 and at Day 29

  8. Proportion of patients requiring mechanical ventilation [ Time Frame: 29 days ]
    Proportion of patients requiring mechanical ventilation

  9. Duration of hospitalization [ Time Frame: 29 days ]
    Duration of hospitalization

  10. Time to discharge or to a NEWS2 score of ≤2 [ Time Frame: 29 days ]

    The time to discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and maintained for 24 hours whichever comes first.

    The NEWS2 is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice presentation or when a patient is being monitored in hospital. The score ranges from 0 (best) to 23 (worst).


  11. Change from baseline in NEWS2 score [ Time Frame: Baseline, Days 3, 5, 8, 11, 15, and 29 ]
    The National Early Warning Score 2 (NEWS2) is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice presentation or when a patient is being monitored in hospital. The score ranges from 0 (best) to 23 (worst).

  12. Change from baseline in SpO2/FiO2 ratio. [ Time Frame: Baseline, Day 15, Day 29 ]
    Change from baseline in peripheral oxygen saturation / fraction of inspired oxygen ratio (SpO2/FiO2 ratio)

  13. Proportion of patients with no oxygen therapy [ Time Frame: Day 15, Day 29 ]
    No oxygen therapy is required if oxygen saturation is ≥ 94% on room air.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patient or guardian/health proxy must provide informed consent (and assent if applicable) before any study assessment is performed.

Male and female patients aged ≥ 12 years (or ≥ the lower age limit allowed by Health Authority and/or Ethics Committee/Institutional Review Board approvals).

Patients with coronavirus (SARS-CoV-2) infection confirmed by polymerase chain reaction (PCR) test or another rapid test from the respiratory tract prior to randomization.

Patients currently hospitalized or will be hospitalized prior to randomization.

Patients, who meet at least one of the below criteria:

  • Pulmonary infiltrates (chest X ray or chest CT scan);
  • Respiratory frequency ≥ 30/min;
  • Requiring supplemental oxygen;
  • Oxygen saturation ≤ 94% on room air;
  • Arterial oxygen partial pressure (PaO2)/ fraction of inspired oxygen (FiO2) < 300mmHg (1mmHg=0.133kPa) (corrective formulation should be used for higher altitude regions (over 1000m).

Exclusion Criteria:

History of hypersensitivity to any drugs or metabolites of similar chemical classes as ruxolitinib.

Presence of severely impaired renal function defined by serum creatinine > 2 mg/dL (>176.8 μmol/L), or have estimated creatinine clearance < 30 ml/min measured or calculated by Cockroft Gault equation or calculated by the updated bedside Schwartz equation.

Suspected uncontrolled bacterial, fungal, viral, or other infection (besides COVID-19).

Currently intubated or intubated between screening and randomization. In intensive care unit (ICU) at time of randomization. Intubated or in ICU for COVID-19 disease prior to screening. Patients who are on anti-rejection, immunosuppressant or immunomodulatory drugs (i.e. tocilizumab, ruxolitinib, canakinumab, sarilumab, anakinra).

Unable to ingest tablets at randomization. Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04362137


Contacts
Layout table for location contacts
Contact: Novartis Pharmaceuticals 1-888-669-6682 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals +41613241111

Locations
Show Show 74 study locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Incyte Corporation
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04362137    
Other Study ID Numbers: CINC424J12301
INCB 18424-368 ( Other Identifier: Incyte Study Code )
2020-001662-11 ( EudraCT Number )
First Posted: April 24, 2020    Key Record Dates
Last Update Posted: September 15, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
COVID-19 pneumonia
cytokine release syndrome
SARS-COV-2
ruxolitinib